Johnson & Johnson | PharmaTimes

First treatment for common bladder cancer recommended by NICE

Ella Day — Thu, 10 Apr 2025 11:22:53 +0000

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration

John Pinching — Wed, 10 Aug 2022 13:04:00 +0000

Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the UK

Lucy Parsons — Fri, 22 Oct 2021 11:36:00 +0000

EUA amendments 'based on the available data and information'

Lucy Parsons — Fri, 28 May 2021 14:23:00 +0000

UK’s Vaccine Taskforce has secured 20 million doses of the vaccine, with initial deliveries expected 'later this year'

Lucy Parsons — Tue, 04 May 2021 09:12:00 +0000

Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma

Lucy Parsons — Mon, 26 Apr 2021 09:42:00 +0000

Advisory committee voted to resume use of the vaccine under its emergency use authorisation

Lucy Parsons — Fri, 12 Mar 2021 09:50:00 +0000

Conditional marketing authorisation closely follows positive opinion from CHMP

Lucy Parsons — Wed, 14 Oct 2020 09:46:00 +0000

Participant in phase III study developed unexplained illness

Selina McKee — Fri, 21 Aug 2020 07:36:00 +0000

The move will expand Janssen's presence in autoimmune diseases

Selina McKee — Thu, 02 Jul 2020 11:13:00 +0000

This marks the first major regulatory approval of a vaccine developed by Janssen